A Phase II Study of Weekly Docetaxel and Topotecan in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
Status:
Completed
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
Primary objective:
To estimate the overall clinical response rate (CR, PR, SD) of weekly docetaxel and weekly
topotecan in women with recurrent platinum resistant ovarian or primary peritoneal cancer.
Secondary objectives:
To access the safety and tolerability of this novel combination chemotherapy regimen of
weekly docetaxel and weekly topotecan in women with recurrent platinum resistant ovarian or
primary peritoneal cancer
To estimate the progression free survival (PFS) and overall survival (OS) for women with
recurrent platinum resistant ovarian or primary peritoneal cancer treated with this weekly
docetaxel and weekly topotecan.